CNDO 109

Drug Profile

CNDO 109

Alternative Names: Allogeneic tumour activated natural killer lymphocytes; CNDO-102; CNDO-109; CNDO-109-AANK Cells; CNDO-109-activated allogeneic NK cell therapy

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University College London
  • Developer Fortress Biotech
  • Class Antineoplastics; Biological intercellular signalling peptides and proteins
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 21 Sep 2015 CNDO 109 is still in phase I/II trials for Acute myeloid leukaemia (Prevention of relapse) in the USA
  • 27 Apr 2015 Coronado Biosciences is now called Fortress Biotech
  • 28 Nov 2012 Phase-I/II clinical trials in Acute myeloid leukaemia (prevention of relapse) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top